# A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males

> **NCT03335254** · PHASE1,PHASE2 · TERMINATED · sponsor: **TesoRx Pharma, LLC** · enrollment: 9 (actual)

## Conditions studied

- Hypogonadism
- Hypogonadism, Male
- Gonadal Disorders
- Endocrine System Diseases
- Testosterone Deficiency

## Interventions

- **DRUG:** TSX-011

## Key facts

- **NCT ID:** NCT03335254
- **Lead sponsor:** TesoRx Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-06
- **Primary completion:** 2018-05-03
- **Final completion:** 2018-05-03
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Incomplete effect
- **Last updated:** 2019-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03335254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03335254, "A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03335254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*